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Trypanothione Reductase:  A Viable Chemotherapeutic 
Target for Antitrypanosomal and Antileishmanial Drug Design
M. Omar F. Khan
College of Pharmacy, Southwestern Oklahoma State University, 100 Campus Drive, Weatherford, 
OK 73096, U.S.A. 
Abstract: Trypanosomiasis and leishmaniasis are two debilitating disease groups caused by parasites of Trypanosoma and 
Leishmania spp. and affecting millions of people worldwide. A brief outline of the potential targets for rational drug design 
against these diseases are presented, with an emphasis placed on the enzyme trypanothione reductase. Trypanothione re-
ductase was identifi ed as unique to parasites and proposed to be an effective target against trypanosomiasis and leishmani-
asis. The biochemical basis of selecting this enzyme as a target, with reference to the simile and contrast to human analogous 
enzyme glutathione reductase, and the structural aspects of its active site are presented. The process of designing selective 
inhibitors for the enzyme trypanothione reductase has been discussed. An overview of the different chemical classes of 
inhibitors of trypanothione reductase with their inhibitory activities against the parasites and their prospects as future che-
motherapeutic agents are briefl y revealed.
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Introduction
Trypanosomiasis and leishmaniasis are among the major debilitating and devastating tropical diseases 
that are targets for the World Health Organization’s special program Research and Training in Tropical 
Diseases (TDR) (Hyde, 1990) and most recently the Drugs for Neglected Diseases initiative (DNDi, 
www.dndi.org). These diseases are caused by the parasites of the genus Trypanosoma and Leishmania. 
The present review focuses on the major human diseases caused by trypanosomal and leishmanial 
infections and the potential targets for designing chemotherapeutic agents against these diseases with 
special emphasis on trypanothione reductase. Table 1 gives an outline of the major human trypanoso-
miasis and leishmaniasis with their global annual disease burdens (as of 1999) in terms of disability 
adjusted life years (DALY).
Table 1.The major trypanosomiasis and leishmaniasis, causative agents, their global burdens in terms 
of Disability Adjusted Life Years (DALY) and current treatments.
Disease Causative agents DALY*  Current Treatments
  (million/year)
African  Trypanosoma brucei 1.2 Suramine, pentamidine,
trypanosomiasis gambiense and   DFMO, tryparsamide
or sleeping T. b. rhodesiense  
sickness 
American  T. cruzi 0.6 Benznidazole, nifurtimox 
trypanosomiasis    
or Chagas disease   
Visceral  Leishmania donovani 1.7 Pentostam, glucantime,
leishmaniasis 
or kalazar   
Dermal  L. major, L. tropica,  aminosidine
leishmaniasis  L. braziliensis, L. mexicana  
or tropical sore   
*Taken from World Health Report 1999, publ. World Health Organization Geneva (1999).
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Suramine (1) and pentamidine (2) are useful 
drugs for treating Human African Trypanoso-
miasis (HAT) during early infection, but being 
highly charged, cannot cross the blood brain 
barrier and are of no use for late stage infection 
with involvement of central nervous system 
(CNS) with either Trypanosoma brucei gambiense 
or T. b. rhodesiense. Melarsoprol (3), a trivalent 
arsenical, or tryparsamide (4) is then used. 
Difl uoromethylornithine (DFMO, 5) is effective 
in treatment of HAT, but is not very effective 
against rhodesiense sleeping sickness where large 
doses must be used, resulting in significant 
side-effects, including bone marrow suppression 
(Meshnick, 1984; Neva and Brown, 1994). 
Nifurtimox (6), a nitrofuran derivative, is the best 
drug currently available for treating Chagas 
disease but is still considered investigational. It 
is thought to kill trypanosomes selectively 
through futile cycling by the formation of 
hydrogen peroxide and toxic oxygen species 
(Docampo and Stoppani, 1979; Le Trant et al. 
1983; Docampo and Moreno, 1984a and b, 1986; 
Neva and Brown, 1994). Benznidazole (7) is of 
equivalent effectiveness and is used in South 
America in the acute stage. Both drugs must be 
given for several months and are associated with 
severe side effects (Neva and Brown, 1994). 
Recently, the present and future prospects of 
chemotherapy of HAT, in addition to the possible 
mode of action and the mechanism of resistance 
of the current chemotherapeutic agents have been 
reviewed (Fairlamb, 2003a).
Pentavalent antimonials e.g. pentostam (8) is 
the recommended treatment for visceral leish-
maniasis but are toxic and developed resistance 
(Croft, 1988; Grogl et al. 1992). Relapse of disease 
or only partial response is more common in Kenya, 
the Sudan, and India than in Mediterranean or Latin 
American kala azar, where a second or longer 
course of treatment is often needed.
Overall, the demand for chemotherapeutic 
agents for the treatment of Chagas disease, 
sleeping sickness and kala azar is desperate. 
Those needing treatment are mainly in impover-
ished rural and urban communities with poor 
housing and limited access to medical attention, 
and in countries where basic healthcare infrastruc-
tures have yet to be developed. Approved 
chemotherapies that are available were developed 
in the fi rst half of the last century (suramine, 
pentamidine, arsenicals and antimonials); some 
would fail today’s more stringent standards for 
drug safety. Given the initial success of a largely 
empirical approach, progress in drug development 
in recent years has been poor and, undoubtedly 
there is great need for new less toxic treatments 
for human diseases by parasitic trypanosomes and 
leishmanias. In view of the economies of the Third 
World countries suffering most from these 
diseases, such drugs will have to be cheap and 
simple to administer.
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Figure 1. Structures of the currently available drugs for the treatment of trypanosomiasis and leishmaniasis.
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Potential Chemotherapeutic 
Targets for Trypanosomiasis 
and Leishmaniasis
In this genomic, proteomic, and bioinformatics 
era of target identifi cation, scores of potential 
targets for antitrypanosomal and antileishmanial 
chemotherapy will be emerging. In the pre-
genomic era, basic research in molecular biology 
and multidimensional research initiatives has 
identifi ed some biological features associated 
with the development of trypanosomiasis that 
have been well documented and studied exten-
sively. Ergosterol biosynthesis, parasite specifi c 
proteases and reductases, purine salvage and 
phospholipid biosynthesis (for review see Urbina, 
2003) could be turned into targets, provided that 
the following two requirements can be met: (a) 
the target must be essential for the survival of the 
parasites, and (b) the target must be such that a 
counterpart in the mammalian host either does 
not exist or is sufficiently different to allow 
selective inhibition (Wang, 1995). The techno-
logical advancements related to post-target 
selection are also important criteria. Because the 
target must be suitable for study at the molecular 
level that include most importantly the high 
throughput screening for which convenient, cheap 
and sensitive assay methods are highly desirable.
Glycolytic pathway
As trypanosomal cells are completely energeti-
cally dependent on glycolysis it might be used to 
develop new trypanocidal drugs (Michels, 1988). 
Compertmentation of glycolytic enzymes is 
generally assumed to result in an enhancement of 
the rate of glycolysis in bloodstream trypano-
somes, approximately 50-times higher than that 
in mammalian cells (Brohn and Clarkson, 1980). 
This appears to be necessary to compensate for 
poor yields of energy. Trypanosomes need to 
replicate every 6 to 8 h in mammalian blood and 
Varian surface glycoproteins (VSGs) must be 
replaced frequently to evade a host immune 
response (Donelson and Rice-Ficht, 1985). Thus 
it has been suggested that inhibition of any one 
of the glycolytic enzymes inside the glycosomes 
may block glycolytic activity and kill bloodstream 
trypanosomes (Clarkson and Brohn, 1976; 
Michels, 1988). The three dimensional (3D) 
structure of T. brucei glycosomal triosephosphate 
isomerase (TIM), determined at 2.4 Å resolution, 
was found to be very similar to that of mammalian 
TIM (Wierenga et al. 1987). The 3D structure of 
glycosomal glyceraldehyde-3-phosphate dehy-
drogenase (GADPH) (Vellieux et al. 1993) could 
provide opportunities for designing selective 
inhibitors as it differs from the mammalian 
homolog (Verlinde et al. 1994; Wang, 1995). 
Bloodstream T. b. brucei imports glucose by 
facilitated diffusion and the uptake of glucose 
apparently represents the rate-limiting step in 
glycolysis. The genes encoding trypanosomal 
glucose transporters are tandemly arranged in a 
multigene family consisting of two homologous 
groups, trypanosome hexos transporter (THT)1 
and THT2. THT1-encoded glucose transporters, 
preferentially expressed in a bloodstream form, 
have a moderate sensitivity to cytochalasin B and 
recognize D-fructose as substrate, thereby distin-
guishing them from the human erythrocyte 
glucose transporter. They are potential targets for 
antitrypanosomal chemotherapy (for review, see 
Wang, 1995).
DNA topoisomerases
Many of the established antiprotozoal agents are 
known to bind to DNA. There are two potential 
sites for DNA binding in members of the kineto-
plastida: nuclear and kinetoplast DNA. In 
general, DNA binding agents would be expected 
to be active against protozoa, but toxicity is a 
major factor. It was assumed that binding to DNA 
leads directly to inhibition of DNA-dependent 
processes, but it is now generally accepted that 
intercalating agents induce topoisomerase II – 
mediated strand breaks in DNA (Brown, 1987). 
Trypanosomal topoisomerase II inhibitors affect 
both nuclear and mitochondrial DNA and may 
prove to be effective and safe antitrypanosomal 
drugs (Shapiro, 1993) as they differ structurally 
from mammalian topoisomerase II (Shapiro and 
Showalter, 1994). DNA topoisomerase I could 
also serve as an intracellular target, as its inhibi-
tion can cause DNA-cleavage and ultimate death 
of trypanosomes (Bodley et al. 1995). 
Ergosterol biosynthesis
Ergosterol biosynthesis is a novel metabolic 
pathway essential for parasitic survival lacking a 
counterpart in the host. Several enzymes of this 
pathway, e.g. squalene synthase, fernesylpyro-
phosphate synthase are capable of depleting 
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As shown in Figure 2, ornithine decarboxylase 
(ODC), S-adenosyl-L-methionine decarboxylase 
(SAMDC) and spermidine synthetase in 
trypanosomes serve crucial functions (Fairlamb 
and Bowman, 1980) and may be potential targets 
for antitrypanosomal chemotherapy. Little is 
known about trypanosomal SAMDC except that it 
did not cross-react with human SAMDC antiserum 
(Tekwani et al. 1992). Detailed comparison of 
mammalian and trypanosomal SAMDCs have not 
yet been done nor have crystal structure and amino 
acid sequence been determined, steps important 
for designing drugs active against this enzyme.
Trypanothione is a conjugate of glutathione 
and the polyamine spermidine. This polyamine 
component of the structure of trypanothione 
disulfi de (T[S]2) rationalized the actions of several 
antitrypanosomal and antileishmanial drugs. For 
example, DFMO (5), the fi rst new drug licensed 
to treat HAT for over 50 years, inhibits ODC, 
which catalyzes the initial step in polyamine 
biosynthesis (Fig. 2), decreasing the trypano-
thione pool. The origin of the trypanocidal effect 
of DFMO has not been established (Fairlamb and 
Cerami, 1992).
Figure 2. Metabolism and function of trypanothione, showing possible sites of action of trypanocidal compounds. The insert above illustrates 
the futile redox cycling by nitro compounds (RNO2) to form hydrogen peroxide (H2O2) and hydroxyl radicals (OH●). Abbreviations: BSO, 
buthionine sulfoximine; DFMO, difl uoromethylornithine; R-As=O, melarsen oxide; Mel T, melarsen trypanothione adduct; PUT, putrescine; 
SPD, spermidine; dSAM, decarboxylated S-adenosylmethionine; MTA, methylthioadenosine (modifi ed from Krauth-Siegel et al. 1987).
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endogenous sterols, and therefore represent viable 
chemotherapeutic targets (for review, see Linares 
et al. 2006).
Purine salvage pathway
Some striking differences between parasites and 
their mammalian host are apparent in purine 
metabolism. Unlike their mammalian host, most 
parasites lack the de novo purine biosynthetic 
mechanisms and rely on salvage pathways to meet 
their purine needs. There are suffi cient distinctions 
between enzymes of the purine salvage pathway 
in host and parasite that can be exploited to design 
specifi c inhibitors or “subversive substrates” for 
the parasitic enzymes. Furthermore, the specifi ci-
ties of purine transport, the fi rst step in purine 
salvage, differ signifi cantly between parasites and 
their mammalian host to allow selective inhibitor 
design (for review see El Kouni, 2003).
Polyamine biosynthesis
The ability to synthesize polyamines (Fig. 2) is 
vitally important for the proliferation of bloodstream 
HAT in an environment defi cient in polyamines. 
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Trypanothione reductase (TR) and the synthetic 
enzyme of trypanothione metabolism found in 
trypanosomatids exemplify unique features of the 
organisms. As shown in Figure 2, trypanothione 
synthesis proceeds from glutathione; the similar 
redox potentials allow for nonenzymatic thiol-disul-
fi de exchange reactions to occur (Fairlamb and 
Cerami, 1992). Considerable advances have been 
made in characterization and inhibitor design against 
TR. The key enzyme of the two-step trypanothione 
biosynthesis, glutathionyl spermidine synthetase, 
was isolated, partially sequenced and kinetically 
analyzed (Koenig et al. 1997). The utilization of 
trypanothione for the reduction of hydroperoxides 
has remained a matter of debate. A trypanothione 
peroxide activity, presumed to substitute for the 
glutathione peroxide activity typical of host metab-
olism (Flohé, 1989), was observed in crude extracts 
of various trypanosomatids (Henderson et al. 
1987a). Consistent failures to isolate putative 
trypanothione peroxidases, and substantial sponta-
neous reaction rates between trypanothione and 
hydrogen peroxide, led to the conclusion that 
trypanothione-dependent peroxide metabolism may 
represent a non-enzymatic event (Carnieri et al. 
1993). Recent discoveries have demonstrated 
(Nogoceke et al. 1997) that the reduction of perox-
ides by trypanothione is an enzymatic process, but 
in contrast to previous expectations, is catalyzed by 
two distinct proteins in concert (Flohé, 1998). 
Lipoamide dehydrogenase (LipDH) is another 
fl avoprotein dependent enzyme, which has been 
discussed as a target molecule for antitrypano-
somal therapy. In T. cruzi, an organism highly 
susceptible to oxidative stress, LipDH participates 
in the redox cycling of nifurtimox, one of the most 
effective anti-Chagas agents (Krauth-Siegel and 
Schöneck, 1995). 
Trypanothione Reductase 
as a Chemotherapeutic Target
In the pre-genomic era investigation of mode of 
action of arsenical drugs and glutathione biosyn-
thesis inhibitor, buthionine sulfoximine (BSO), 
gave rise to the discovery of trypanothione, unique 
to trypanosomes and absent from the mammalian 
cells (Fairlamb et al. 1985). In mammals, potential 
redox damage meets the glutathione (GSH)-based 
system as a fi rst defense, during the course of 
which glutathione disulfi de (GSSG) is formed 
(Equation 1).
Regeneration of protective GSH from GSSG is 
catalyzed by GR. In trypanosomes and leishmanias 
an analogous system has evolved (Fairlamb and 
Cerami, 1992) insofar as the disulfi de (T[SH]2) differs 
from GSSG by the presence of a spermidine cross-link 
between the two glycyl carboxyl groups (compare 
GSSG and T[S]2). The enzyme TR reduces T[S]2 to 
dithiol T[SH]2 in a manner analogous to GR (Fig. 3). 
With this discovery of a fundamental metabolic differ-
ence, TR was proposed and amplifi ed further as a 
target for the rational design of antitrypanosomal and 
antileishmanial drugs (Fairlamb et al. 1985; Shames 
et al. 1986; Benson et al. 1992; Hunter et al. 1992; 
Schirmer et al. 1995).
Unlike human hosts, trypanosomes contain TR 
instead of analogous enzyme GR to process their 
cognate substrates trypanothione and glutathione, 
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respectively. Parasite TR does not process GSSG and 
host GR does not reduce T[S]2 (Shames et al. 1986; 
Krauth-Siegel et al. 1987). Selective inhibitor design 
is probable, due to the mutually exclusive recognition 
and rejection of cognate substrates between host and 
parasite (Shames et al. 1986; Krauth-Siegel et al. 
1987; Schirmer et al. 1995). Efficient selective 
blockade of TR would be expected to compromise 
the redox defences of the parasites, increasing their 
sensitivity to redox-damage based drugs, e.g. nifur-
timox. A TR inhibitor might be expected to be drug 
in its own right or for co-administration with a redox-
active drug e.g. nifurtimox. The later case may even 
provide synergy, allowing use of lowered doses of 
the redox drug (Chan et al. 1998). 
TR is a member of the large well-characterized 
protein family of FAD-dependent NADPH oxido-
reductases (reviewed in Williams, 1992) and share 
close structural and mechanistic similarities with 
that of GR (summarized in Table 2). It is a dimeric 
protein of monomer molecular mass 52kDa, 
providing FAD-binding, NADPH-binding, central 
and interface domains. There are two identical 
active sites, formed by residues of the FAD, 
NADPH, and central domains of one monomer and 
the interface domain of the other (Fig. 4).
Validating suitability of trypanothione 
reductase as a target
To validate TR as a viable target for rational drug 
design, inhibition of TR in vitro should correlate 
with an observable effect in vivo. This is a diffi cult 
test to satisfy unambiguously; biochemical and 
molecular biological attempts had been made to 
probe TR as a reasonable drug target. In absolute 
terms, disruption or deletion of the TR genes in 
parasites should be lethal. Over-expression of TR 
in transfected L. donovani promastigotes was not 
found to alter the sensitivity to hydrogen peroxide 
indicating that the regeneration of T[SH]2 from its 
disulfi de after oxidative challenge is not the rate-
determining feature of the defense system (Kelly et 
al. 1993). Over-expression of TR in T. cruzi led to 
gene rearrangements when antisense modulation of 
TR expression was attempted (Tovar and Fairlamb, 
1996). Disruption of two of the TR alleles of Leish-
mania failed to produce a null mutant, and actually 
produced a third copy of TR gene by genomic rear-
rangement to a larger chromosome (Dumas et al. 
1997). Down-regulation of TR using a trans-domi-
nant mutation strategy demonstrated that even with 
only 15% residual TR activity, promastigote growth 
is still supported in culture (Tovar et al. 1998a). It 
was proposed that any rationally designed inhibitor 
of TR must attain >85% inhibition for activity as an 
antileishmanial species, but it was pointed out that 
such cells are more sensitive to oxidative insult, such 
as the oxidative burst of macrophages, and that 
clinically usable TR inhibitors may need to be as 
effective in vivo (Tovar et al. 1998a). Later it had 
been demonstrated that TR absence is incompatible 
with parasite survival and validated TR as a bonafi de 
drug target. As it was not possible to obtain viable 
Leishmania devoid of TR catalytic activity, specifi c 
inhibitors of this enzyme are likely to be useful 
antileishmanial agents for chemotherapeutic use 
(Tovar et al. 1998b).
Sequence alignment of TRs and human GRs 
(hGRs) showed that relative to TR hGR has an N-
terminal extension, a C-terminal truncation and 
several deletion and insertions throughout the 
sequence. The most striking regions of homology 
are 14-residue sequence containing the redox-active 
cysteine residues and the 10-residue sequence 
containing the active site histidine. Although the 
disulfi de-binding site in TR in general rather closely 
resembles that for GSSG in GR, they have over 
1000-fold selectivity for their cognate substrates, 
the molecular basis for which involves size, charge 
and hydrophobicity of their active sites. TR binding 
site is much wider in the outer region (~22 Å × 20 
Å × 28 Å) due to different orientations of two helices 
Figure 4. Structure of trypanothione reductase with FAD, NADPH 
and trypanothione bound (modifi ed from Bond et al. 1999).
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in the FAD domains (Kuriyan et al. 1991). The TR 
active site is more hydrophobic and has an overall 
negative charge to attract its positively charged and 
more hydrophobic polyamine containing cognate 
substrate trypanothione and repel the negatively 
charged smaller host substrate glutathione. 
Conversely, the GR active site is smaller and posi-
tively charged, repelling the larger and positively 
charged trypanothione. The X-ray crystal structures 
of TRs from Crithedia fasciculata (Kuriyan et al. 
1991; Hunter et al. 1992), and T. cruzi have been 
solved (Lantwin et al. 1994; Zhang et al. 1996). The 
crystal structure of TR in complex with trypano-
thione was solved (Bond et al. 1999) as was the 
crystal structure of TR complexed with the alterna-
tive substrate glutathionyl spermidine (Bailey et al. 
1993) and with the weak, but selective, inhibitor 
mepacrine (Jacoby et al. 1996). As already pointed 
out, a convenient screening technology is highly 
desirable for a suitable substrate to expedite the drug 
discovery process. To this end, a convenient colo-
rimetric plate assay suitable for automated high-
throughput screening has been developed by 
Hamilton et al. (2003). 
One disadvantage of selecting TR as a drug 
target for the development of broad-spectrum 
antiparasitics is that intracellular trypanothione 
concentrations vary from 0.3 mM in African 
trypanosomes to ~3.0 mM in Leishmania spp., 
>99% of which is in the reduced form. As soon as 
TR is inhibited, T[S]2 will start to accumulate due 
to continuing intracellular oxidant process. It is not 
currently known what T[S]2/T[SH]2 ratio is lethal 
to the parasite. It has been suggested that the design 
of competitive inhibitors with Ki-values in nM 
range will be required, and the design of irreversible 
inhibitors may represent a better strategy for drug 
development (Fairlamb, 2003b).
The following section will focus on recent discov-
eries of different classes of TR inhibitors, which 
demonstrated antiparasitic activity and promise of 
development of newer chemotherapeutic agents.
Rational drug design based on 
trypanothione reductase as a target
The homology modeling of TR (Benson et al. 1992) 
with that of hGR shed light on the structural aspects 
of the enzyme also in addition to its substrate-
binding mode from a theoretical perspective. Studies 
with various alternative peptide substrates demon-
strated that the spermidine moiety of trypanothione 
could be conveniently replaced with N,N-dimethyl-
aminopropylamide (dmapa) without loss of 
substrate activity. Subsequently, a series of alterna-
tive γ-glutamyl-modifi ed trypanothione substrates 
were synthesized. The discovery that a benzyloxy-
carbonyl (Z) group represented a suitable replace-
ment resulted in (Z.Cys.Gly.dmapa)2 as a convenient 
alternative assay substrate  in which the Z group 
occupies a hydrophobic pocket near Phe396’ of TR 
(Henderson et al. 1987b; El-Waer et al. 1991, 1993a 
and b;  Marsh and Bradley, 1997). This pocket was 
since named the Z-site, approximately enclosed by 
Phe396’, Pro398’ and Leu399’. This initial advance-
ment in structural aspects of TR active site prompted 
the discovery of peptide inhibitors (Garforth et al. 
1994; McKie et al. 2001; Chan et al. 2002). The fi rst 
rationally designed non-peptide inhibitors are repre-
sented by the tricyclic ring structures that are 
competitive versus trypanothione (Benson et al. 
1992). Progress has been made in discovering large 
classes of inhibitors of TR over recent years, which 
are also found to be lethal to parasites in vitro.
The tricyclic compounds 
and congeners
Molecular modeling approaches were useful in 
identifying tricyclic antidepressants including 
phenothiazines and related structures (e.g. 9, 10) 
and mepacrine (11) (Fig. 5) as competitive 
inhibitors of TR but not GR (Benson et al. 1992; 
Jacoby et al. 1996; Chan et al. 1998). The tricyclic 
moiety of these compounds were shown to lodge 
against the hydrophobic wall of TR active site 
formed by Trp21 and Met113, with the amino-
propyl side chain pointing towards the Glu466’ 
and Glu467’ residues. The synthesis and biolog-
ical evaluation of a series of dibenzazepine 
analogs (Garforth et al. 1997), N-acylpromazines, 
2-substituted phenothiazines, and trisubstituted 
promazines failed to show any improvements over 
the parent leads (Chan et al. 1998).
The antimalarial drug mepacrine (11), an acri-
dine derivative, is also a competitive inhibitor of 
TR. The acridine ring also aligns to the hydro-
phobic wall of TR formed by Trp21 and Met113, 
but the alkylamino side chain point towards Glu18, 
unlike the tricyclics described above (Bonse et al. 
1999). Sulfonamides and urea derivatives of 
mepacrine with varying methylene spacer lengths 
(e.g. 12, 13) were found to be superior inhibitors 
of TR relative to mepacrine with the best inhibitors 
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Figure 5. Structures and activities of tricyclic inhibitors of trypanothione reductase.
being 40-fold more potent (Chibale et al. 2001). A 
series of synthetic 9,9-dimethylxanthene deriva-
tives (e.g. 14) were shown to be competitive 
inhibitors of TR which are comparable to known 
tricyclic inhibitors of TR (Chibale et al. 2003).
It is important to note that as required in prin-
ciple for an ideal drug target, inhibition of TR in 
vitro should also correlate with antiparasitic 
activity in vitro against T. brucei, T. cruzi and 
L. donovani. However, no strong correlation 
between TR-inhibitory activity and in vitro anti-
parasitic activity was observed indicative of unfa-
vorable pharmacokinetic profi les.
2-Aminodiphenylsulfi des 
and its congeners
Modifi cation of the central ring of the phenothi-
azines furnished the 2-aminodiphenylsulfides, 
termed ‘open chain chlorpromazines’. Using a 
microplate assay to screen TR inhibitors, this group 
of compounds was discovered to be potent compet-
itive inhibitors (Fig. 6). Compound 15 was the best 
inhibitor in the preliminary series (Fernandez-
Gomez et al. 1995). Based on these results and 
molecular modeling studies, a series of bis 
(2-aminodiphenylsulfi des) were synthesized and 
compound 16 was shown to be the most potent in 
this series (Girault et al. 1997). Further improve-
ment was evident with a newer generation of 
bis(2-aminodiphenylsulfides) (e.g. 17) corre-
sponding to attachment of an additional hydro-
phobic side to an analog of compound 16. The 
large volume of the TR active site justifi ed the 
introduction of an additional hydrophobic group 
to the end of the side chain (Girault et al. 2001).
All the compounds demonstrated antiparasitic 
activity in vitro at low micromolar ranges. 
However, no correlations between TR inhibition 
and in vitro antiparasitic activity were apparent.
Quaternary alkylammonium 
compounds
The quaternization of tertiary alkylamine ω-nitrogen 
atom of chlorpromazine by substituted benzyl and 
other aromatic or heterocyclic groups resulted the 
discovery of quaternary alkylammonium pheno-
thiazines as a new class of linear competitive 
inhibitors of TR (Fig. 7) (Khan et al. 2000). The 
permanent positive charge on the distal nitrogen 
atom of the tricyclic’s side chain contributed to 
binding was estimated as ≥5.6 kcal.mol-1 by 
comparison with the analog with cationic nitrogen 
atom of the quaternary (18) replaced by an ether 
oxygen atom (19). The major contribution to 
improving Ki value and inhibition strength 
was accomplished by incorporating the hydro-
phobic N-benzyl substituents. The best inhibitor 
identified was compound 19, containing a 3, 
Drug Target Insights 2007: 2
138
Khan
N
S
N+H3C
H3C
Cl
Cl
ClCl
-
18, Ki = 0.12 M
(Khan et al. 2000)
N
S
O
Cl
Cl
Cl
19, no inhibition at 50 M
(Khan et al. 2000)
NH
S
N+H3C
H3C
Cl
Cl
ClCl
-
20, Ki = 1.7 M
(Parveen et al. 2005)
Figure 7. Structures of quaternary alkylammonium compounds with their anti-TR activities.
4-dichlorobenzyl substituent (~2 orders of 
magnitude >chlorpromazine). 
Detailed molecular modeling studies helped to 
establish docking orientations and energies by 
revealing involvement of: (i) the major hydro-
phobic pocket (Trp21, Met113, Tyr110), (ii) the 
“Z”-site (Phe396’, Pro398’, Leu399’) and (iii) the 
ionic interactions possible for the quaternary 
cationic nitrogen with nearby side chains of 
Glu466’ and Glu467’ (Fig. 8) (Austin et al. 1999, 
Khan et al. 2000). This “three point attachment”, 
a concept initially designed by Ogston (1948) to 
explain chiral specifi city of enzymes, has allowed 
on average a 30-fold improvement of Ki values 
against TR (Khan et al. 2000).
Similarly, the quaternization of the side chain 
tertiary nitrogen atom of the ‘open chain chlorprom-
azines’ also showed improvements in inhibition up to 
NH
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Figure 6. Structures of 2-aminodiphenylsulfi des with their anti-TR activities.
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40-fold. The most potent compound synthesized from 
this series was the 3, 4-dichlorobenzyl analog (20) 
(Parveen et al. 2005). All analogs demonstrated strong 
inhibition, some in lower nM ranges, against the blood 
stream form of T. brucei. Antiparasitic activity was 
not solely determined by the inhibition strength against 
TR; a strong contribution from hydrophobicity was 
also observed. Although active against L. donovani, 
none showed major improvement in this activity rela-
tive to their parent compounds. Some of the analogs 
also showed improved inhibition against the amasti-
gote stage of T. cruzi with ED50 values <1 µM (Khan 
et al. 2000; Parveen et al. 2005).
Polyamine derivatives
As shown in Scheme 1, the natural disulfide 
substrate of TR, T[S]2, differs from the analogous 
host’s GSSG only by the presence of a spermidine 
(a polyamine) cross-link between the two glycyl 
carboxyl groups. This discrimination between 
parasite and host substrate served as a criterion for 
developing polyamine derivatives as selective 
inhibitors of TR (O’Sullivan and Zhau, 1995; 
O’Sullivan et al. 1996, 1997; Baillet et al. 1996; Li 
et al. 2001; Bi et al. 2006). This approach led to the 
discovery of series of potent selective competitive 
inhibitors of TR, several selected compounds are 
included in Figure 9 (compounds 21, 22).
Solid phase synthesis approaches allowed for the 
expedient synthesis of polyamine-based focused 
libraries as potential TR inhibitors. Several potent 
inhibitors were identifi ed with low nM activity 
(Orain and Bradley, 2001; De Luca et al. 2003).
Most of these compounds also displayed potent 
in vitro antiparasitic activity against T. brucei with 
ED50 values <1 µM (O’Sullivan et al. 1997; Li et al. 
2001; Bi et al. 2006). These preliminary antiparasitic 
activity in vitro are suggestive of their TR involve-
ment although well correlation between TR-inhibi-
tion and trypanocidal activity were not evident.
Bisbenzylisoquinoline alkaloids
The bisbenzylisoquinoline alkaloids were also 
shown to be potent inhibitors of TR and trypano-
cidal agents (Fournet et al. 1998, 2000). Six of the 
alkaloids evaluated displayed potent trypanocidal 
activity in vitro against T. cruzi with ED50 values 
<100 µM. The best TR inhibitor, cepharanthine 
Figure 8. Compound 18 docked into active site of TR to show major 
interactions (taken from Austin et al. 1999).
Figure 9. Structures and trypanothione reductase inhibitory activities 
of polyamine derivatives.
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Figure 10. Bisbenzyleisoquinoline alkaloid.
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(23), had an I50 value of 15 µM which is the same 
order of magnitude as its ED50 against the parasites, 
suggesting that inhibition of TR could be the 
mechanism of their trypanocidal activities.
Natural products
Natural products may be considered as “nature’s 
medicine chest” and have served as a potential 
source of TR-inhibitors. The natural antihyper-
tensive agent, kukoamine A (24), a bis (trihydro-
cinnamoyl) spermidine derivative, fi rst isolated 
from Lycium chinense, was identifi ed as a mixed 
type of inhibitor of TR (Ponasik et al. 1995).
Virtual screening of a large number of chemical 
databases, using the TR active site as the targeted 
template, identified the natural spermine-based 
macrocyclic alkaloid lunarin (25) (originally isolated 
from Lunaria biennis) as TR-inhibitor, which was 
shown to inhibit the enzyme in a time-dependent 
manner (Bond et al. 1999). Further investigation 
with synthetic derivatives confi rmed the importance 
of the unique structure of the tricyclic core as a motif 
for inhibitor design and revealed that the non-natural 
enantiomer may be a more suitable scaffold upon 
which thiophilic groups may be presented (Hamilton 
et al. 2006). Ajoen (26) a garlic derived natural 
sulfur-containing compound was established as an 
irreversible inhibitor and subversive substrate of 
both TR and GR (Gallwitz et al. 1999). Most of 
these natural products also inhibited the parasites in 
vitro in one way or another.
Irreversible inhibitors
The anticancer nitrosourea drug carmustin was the 
fi rst ligand to display irreversible inactivation of 
TR, but non-specifi cally as also inactivated hGR, 
by carbamoylating an active site cystinyl residue, 
which becomes accessible after being reduced by 
NADPH (Schirmer et al. 1995). Ajoen (26), as 
previously mentioned as a natural product inhibitor, 
is an irreversible non-specifi c inhibitor of TR 
(Gallwitz et al. 1999). The fi rst rationally designed 
and selective irreversible inhibitors of TR include 
the Pt-complexes of terpyridine derivatives (e.g. 
27), which inhibit the reduced TR, presumably 
through occupying the Cys52 by replacing its 
fourth pyridine ligand (Bonse et al. 2000). 
Coupling the irreversible ligand (terpyridine)Pt2+ 
complex with an 9-aminoacridine derivative (a 
competitive inhibitor) furnished mixed-type 
inhibitors (e.g. 28) (Inhoff et al. 2002). An impor-
tant advancement was made with the quinacrine 
mustard (29), which was shown to selectively and 
irreversibly inactivate TR in a time-dependent 
manner with a stoichiometry of two inhibitors 
bound per monomer. The rate of inactivation was 
dependent upon the oxidative states of TR, with 
NADPH-reduced TR form being inactivated faster. 
The structure of TR-quinacrine mustard-adduct 
solved to 2.7Å revealed that two molecules of 
ligand are bound in the trypanothione binding site 
of TR. Each acridine moiety interacts through π-
stacking, while only one of the acridine groups 
interacts with a trypanothione residue in a similar 
fashion (Saravanamuthu et al. 2004).
Recently, several Mannic bases (e.g. 30) were 
shown by Lee et al. (2005) to be irreversible 
inhibitors of TR. HPLC, NMR and MS analyses 
were performed to delineate their mechanism of 
action and found that divinyl ketone are the key 
intermediates to irreversibly inhibit TR. ESI- and 
MALDI-TOF-MS of TR, modifi ed by Mannic base 
or corresponding divinyl ketone, demonstrated 
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Figure 11. The natural product inhibitors of trypanothione reductase.
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specifi c alkylation of Cys52 in a manner as shown 
in Figure 13 (Lee et al. 2005). 
Sixteen novel Pd-complexes of the bioactive 
nitrofuryl thiosemicarbazones were synthesized and 
tested for their in vitro activity (Otero et al. 2006). 
Most complexes showed higher in vitro trypanocidal 
activity against T. cruzi than the standard drug nifur-
timox. Overall, the activities of Pd complexes ≥their 
parent compounds. It has been suggested that main 
trypanocidal mechanism was the production of 
oxidative stress as a result of their bioreduction with 
the reductive enzymes, although strong DNA-adduct 
formation was also evident (Otero et al. 2006).
Subversive substrates 
of trypanothione reductase
Nifurtimox (6) and related compounds  exert their 
parasiticidal activity through acting as futile, super-
oxide ion producing substrates of TR . TR and GR 
reduce these futile, superoxide ion producing 
substrates in a single electron step (NADPH + 
2RNO2 → 2RNO2•‾ + 2H+; 2RNO2•‾ + O2 → 
2RNO2 + O2•‾), a process by which NADPH and 
O2 are wasted and T[SH]2 is inhibited/oxidized by 
scores of newly formed superoxide ions causing a 
reduction in thiol/disulfi de titer and thus producing 
oxidative stress (Henderson et al. 1988; Schirmer 
et al. 1995). This group of compounds, known as 
‘subversive substrates’ or ‘turncoat inhibitors’, are 
best represented by nitrofurans or quinones, 
chemically modified to take into account the 
substrate specifi city for TR over GR (Cenas et al. 
1994a and b). Thus, chinifur (31), a nitrofuran 
derivative with a positively charged side chain, 
was discovered as a selective inhibitor and subver-
sive substrate of TR (Cenas et al. 1994a). Recently, 
the anti-TR activities of a series of nitrofuran and 
nitroimidazole derivatives were studied to examine 
the mechanism of action of different types of 
N
NN
Pt2+
N
Br
27
N
NN
Pt2+
S
S
OH
H
N NH+
2NO3-
MeO
Cl
28
HN
N
MeO
Cl
CH3
N
Cl
Cl
29
Figure 12. Structures of irreversible inhibitors of trypanothione reductase.
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nitro-group containing compounds. The results 
indicated that the nitrofurans, e.g. nifurtimox act 
as futile-cyclers as discussed above, whereas 
5-nitroimidazoles, e.g. megazole (32) act as thiol 
scavengers particularly for T[SH]2 thus reducing 
the thiol/disulfi de titer which is detrimental for the 
parasites’ survival (Maya et al. 2003). Vega-Teijido 
et al (2006) explored three possible binding sites 
of TR and GR, i.e. the active site, the dimer inter-
face and the NADPH binding site to study the 
mechanism of action of nitrofuran and nitrothio-
phene analogs. It has been suggested that this class 
of compounds act as either uncompetitive or mixed 
inhibitors of TR. Moreover, it has also been indi-
cated that the presence of an α-helix connecting 
the active site of TR with the interface may be 
crucial for charge-transfer processes.
1,4-naphthaqiuinone derivatives (e.g. 33) are 
examples of quinine-based subversive substrates 
of TR, designed after plumbagin. Compound 33 
proved to be a potent subversive substrate and 
an effective uncompetitive inhibitor of TR 
versus T[SH]2 and NADPH (Salmon-Chemin et 
al. 2001). 
Most of these compounds were potent inhibitors 
of the parasites in vitro .  For a series of 
naphthaquinones, a correlation between their 
potency as subversive substrates in vitro and 
trypanocidal activity in vivo has been demonstrated 
(Salmon-Chemin et al. 2001). This ‘alternative 
approach to chemotherapy of Chagas disease’ has 
been considered one of the most promising 
advances. 
Chemotherapeutic Prospects 
of the Trypanothione Reductase 
Inhibitors
For an enzyme inhibitor to become a practical 
drug, several criteria must be met: (i) the 
biochemical pathway that is inhibited must be 
related to the disease state in such a way that 
inhibition of that pathway in a patient is thera-
peutic; (ii) the enzyme inhibitor must be specifi c 
so that unwanted inhibition of other pathways or 
receptors does not occur at therapeutic doses; 
(iii) the compounds must have the pharmacoki-
netic characteristics of a practical drug, i.e. must 
be absorbed, must penetrate to the site of action 
and must have a reasonably predictable dose-
response relationship and duration of action; (iv) 
the compound must have an acceptable toxico-
logical profi le in animals, and the results of 
clinical studies in humans must demonstrate an 
appropriate balance between benefi ts and risks 
in therapeutic use; (v) the compound must survive 
a long and expensive clinical development 
process and ultimately be approved by regulatory 
agencies; (vi) the compound must be economi-
cally viable in the marketplace and compete 
successfully with other therapeutic alternatives 
(Crout, 1989). The criteria (i) and (ii) have 
already been addressed while selecting the target, 
and thus, all of the above mentioned inhibitors 
have fulfi lled them. Pharmacological and toxi-
cological studies in animal models are needed to 
meet other criteria.
Although many potent inhibitors of TR have 
been discovered through enzyme screening, in 
vivo evaluation of these lead compounds are scant. 
Several polyamine derivatives that were shown 
to be potent trypanocidals in vitro (with ED50 
values in submicromolar ranges) failed to prolong 
the lives of experimental mice infected with 
trypanosomes or to cause a signifi cant decrease 
in bloodstream parasitemia of infected mice 
(O’Sullivan et al. 1997). However, none of the 
compounds exerted overt toxicity in mice. It has 
been suggested that the lack of in vivo trypano-
cidal activity may be due to their rapid elimination 
and/or metabolism. Since these compounds are 
reversible inhibitors of TR, concentrations of 
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Figure 14. Structures and activity of subversive substrates of trypanothione reductase.
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these compounds may not be maintained, and as 
a result, TR activity will not be signifi cantly 
decreased (O’Sullivan et al. 1997). It has also 
been suggested that converting reversible inhibi-
tors into irreversible inhibitors through complex-
ation with metal ions might be a reasonable 
strategy for identifying improved leads with 
enhanced in vivo profi les. Clomipramine and 
thioridazine were shown to be effective in treat-
ment of mice with experimental Chagas disease 
(Rivarola et al. 2001, 2002). The investigation of 
effects of clomipramine on T. cruzi infected mice 
demonstrated that clomipramine at 5 mg/kg daily 
doses for 30 days, or two doses of clomipramine 
40 mg/kg given intraperitoneally at 1h and 7 days 
after infection, was not toxic for the host, but was 
effective against the parasite. Parasitamiasis 
became negative and only mild heart structural 
and elecctrocardiographic alterations were 
detected in chronic phase in the group treated with 
clomipramine 5 mg/kg. In mice treated with 40 
mg/kg, none of these alterations was detected 
(Rivarola et al. 2001). Overall, it has been shown 
that clomipramine and thioridazine signifi cantly 
modifi ed the natural evolution of the infection. 
Cardiac function and survival of infected and 
treated animals were not different from nonin-
fected animals. Thioridazine or clomipramine are 
currently registered as drugs (antipsychotics) and 
meet all the above mentioned criteria. However, 
to consider them as antitrypanosomal drugs, dose 
becomes an important obstacle, since they need 
to be active at a dose which is known to be toler-
ated by psychiatric patients without causing 
adverse events. Apart from their potent in vitro 
activity and a preliminary report of in vivo 
activity, more detail studies are needed to estab-
lish their effi cacy and safety and also to improve 
their antiparasitic potency. Overall, it would not 
be overenthusiastic to consider phenothiazines 
and related tricyclic antidepressants and the other 
inhibitors of TR as important drug leads for devel-
opment of future chemotherapy against trypano-
somal and leishmanial infections.
Conclusion
The demand for chemotherapeutic agents for the 
treatment of Chagas disease, sleeping sickness and 
kala azar is desperate. An account of the different 
possible targets for rational drug design with 
special emphasis on trypanothione reductase has 
been focused. TR has been established as a poten-
tial target in several studies although it is not 
universally accepted. The literature, molecular 
graphics and other medicinal chemistry approaches 
have led to the development of a large class of 
compounds as inhibitors of TR and the parasites. 
Considerable progress have been made in terms of 
identifi cation, validation and inhibitor design based 
on trypanothione reductase as a target, which will 
be milestones towards the goal of developing 
chemotherapy against these devastating diseases. 
This review has revealed several approaches based 
on TR towards the development of new drugs 
against the parasitic diseases. Reasonable activity 
against parasites living in both culture and in 
mouse macrophases has been demonstrated by 
most classes of compounds, full activity against 
whole animal model to be achieved. It has been 
suggested that the alternative approaches like 
subversive substrates and metal bound inhibitors 
would be advantageous in achieving reasonable in 
vivo activity against the parasite infection. Only 
the phenothiazines and related tricyclic antidepres-
sants were shown to reduce parasite burden in 
infected mice. Development of the quaternary 
alkylammonium chlorpromazines and congeners, 
with an additional hydrophobic moiety provided, 
on an average, up to about 30-fold more potent 
inhibitors of TR. The charge on N+ is needed for 
interaction at the Glu466’ or Glu467’ of the enzyme 
active site, the tricyclic or equivalent moiety 
interacts with the major hydrophobic cleft and the 
second hydrophobic moiety may interact with 
Z-site. Studies with other classes of inhibitors, in 
addition to the TR:inhibitor complex’s X-ray 
crystal structure, provided similar TR:inhibitor 
interactive motifs. As with any rational drug design 
case at the current stage of computational 
development, the problem of bioavailability, 
pharmacokinetic, metabolism and targeting have 
not been addressed. The prodrug approach might 
be a reasonable step in correcting some of the 
aforementioned problems in developing TR 
inhibitors with observable effects in vivo and might 
open a new path towards the development of drugs 
against these parasitic diseases.
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